Ossium Health, a clinical-stage bioengineering company with a first-of-its-kind bone marrow banking platform for processing and deploying hematopoietic stem cells and stem cell-based therapies, ...
Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...
Astellas' gene therapy programmes – largely stemming from its $3 billion takeover of Audentes Therapeutics – have been under a shadow since AT132 ran into trouble, amid concerns that the adeno ...
In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
The collaboration will also use Astellas’ universal donor cell and gene editing technology it ... rights to develop and market resulting T-cell therapy products using its proprietary process ...
Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...
The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback